HK Stock Market Move | IMPACT THERAP-B (07630) opens over 7% higher; Senaparib receives positive CHMP opinion; recently entered into an exclusive collaboration with Pharmanovia.

IMPACT THERAP-B (07630) opened over 7% higher, up 7.44% as of press time at HK$14, with a turnover of HK$2.3492 million. On the news front, on September 18, IMPACT THERAP-B issued an announcement that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of the marketing authorization (MA) for Sepalna (senaparib), which is intended for the maintenance treatment of advanced epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Following the CHMP's recommendation for approval, senaparib will be submitted to the European Commission (EC) for a final decision. Once approved by the European Commission, senaparib will be authorized for marketing in all EU member states and European Economic Area countries. It is understood that Impact Therapeutics and Pharmanovia entered into an exclusive collaboration in July 2026, under which Impact Therapeutics granted Pharmanovia exclusive rights to manufacture, develop, and commercialize senaparib in 66 countries (including all 27 EU member states, as well as the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries in the Middle East and North Africa region) for maintenance monotherapy treatment of advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer.